Silverback therapeutics layoffs11/23/2023 This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. To learn more, visit Forward-Looking Statements Silverback Therapeutics is located in Seattle, Washington. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Poster Title: SBT8230, an ASGR1-directed TLR8 ImmunoTAC therapeutic for the treatment of chronic hepatitis B virus, demonstrated favorable preclinical tolerability with liver-localized activityĬategory: Hepatitis B: Therapeutics: New Agents The poster is now available on the AASLD website and on the Silverback website here. “We look forward to initiating Phase 1-enabling toxicology studies in the first quarter of 2022.” Moreover, our SBT8230 mouse surrogate was shown to reduce HBV surface antigen and drive seroconversion in an AAV-HBV mouse model consistent with the potential to generate immune responses associated with functional cures,” said Valerie Odegard, Ph.D., president & chief scientific officer of Silverback Therapeutics. This results in myeloid cell activation in liver, but not in blood. “Our preclinical studies demonstrate that SBT8230 is efficiently delivered to the liver. SBT8230 comprises a TLR8 agonist conjugated to an antibody specific to the liver-restricted receptor, ASGR1, and is designed to promote functional cures in chronic HBV (cHBV) through activation of an anti-viral immune response in a liver-localized manner. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |